Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Novartis To Launch Five New Biosimilar Drugs By 2020

XTALKS VITALS NEWS

Biosimilar

The company says that the expansion will further reaffirm Sandoz’s commitment to providing less expensive versions of biologic drugs.

Share this!

June 21, 2016 | by Sarah Massey, M.Sc.

Novartis’ generics division, Sandoz, has announced that it plans to push five new biosimilar drugs through the product pipeline all the way to approval by 2020. The company says that the expansion will further reaffirm Sandoz’s commitment to providing less expensive versions of biologic drugs.

Tweet: Novartis’ Sandoz to push five new #biosimilar drugs to approval by 2020 http://ctt.ec/sLUV9+

Sandoz has plans to file applications for marketing approval for 11 biosimilar drugs in both the US and in Europe, by the end of 2017. The company has already reached the half-way point by filing six of the 11 biosimilar applications.

Sandoz’s current biosimilar offerings include Omnitrope (somatropin) and Binocrit (epoetin alfa) in Europe, and Zarxio (filgrastim-sndz) in the US. If all of the company’s biosimilar applications are approved by regulatory agencies, Sandoz may have nearly three times as many products on the market in just four years.

Novartis has also pledged to spend $1 billion on biosimilar manufacturing between 2010 and 2020. In the past six years, the company has already expanded operations at its manufacturing plants in Schaftenau and Kundl, Austria.

Biosimilars are the generic versions of biologic drugs, and are considered to have clinically comparable effects as their branded counterpart. Once the patent-exclusivity period for a given biologic has expired, biosimilars companies are free to develop less-expensive, copy-cat versions.



Investment into biosimilars has been spurred on by the recent patent expirations for top-selling biologics, including Humira and Remicade. While many biosimilars have been long-established on the European market, the US is only just starting to enter the space.

Novartis' Zarxio – a biosimilar of Amgen’s biologic drug, Neupogen – was the first ever biosimilar to win US Food and Drug Administration (FDA) approval in 2015. The regulatory agency has since approved a Remicade biosimilar developed by Celltrion and Pfizer.

Novartis plans to release biosimilar versions of Enbrel, Humira, Neulasta, Remicade, and Rituxan over the next few years. In 2015, those five biologics generated $44 billion in worldwide revenue.

“Biologics have revolutionized treatment of many disabling and life-threatening diseases but far too many people who need these medicines are not able to access them,” said Richard Francis, CEO of Sandoz. “At Sandoz, we are committed to significantly broadening patient access to biologics with a series of major biosimilar launches over the next few years.”


Keywords: Biosimilar, Biologic, FDA


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.